Insider Trading Alert - ACTG, RNR And ICPT Traded By Insiders

Yesterday, May 4, 2016, 86 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,916.49 to $4,828,179.42. Highlighted Stocks Traded by Insiders: Acacia Research (ACTG) - FREE Research Report Graziadio G Louis Iii, who is Director at Acacia Research, bought 8,200 shares at $4.74 on May 4, 2016. Following this transaction, the Director owned 198,131 shares meaning that the stake was boosted by 4.32% with the 8,200-share transaction. The shares most recently traded at $4.64, down $0.10, or 2.07% since the insider transaction. Historical insider transactions for Acacia Research go as follows:

  • 4-Week # shares bought: 120,000
  • 4-Week # shares sold: 34,273
  • 12-Week # shares bought: 259,196
  • 12-Week # shares sold: 34,273
  • 24-Week # shares bought: 313,997
  • 24-Week # shares sold: 34,273
The average volume for Acacia Research has been 796,400 shares per day over the past 30 days. Acacia Research has a market cap of $232.6 million and is part of the services sector and diversified services industry. Shares are up 7.46% year-to-date as of the close of trading on Wednesday. Acacia Research Corporation, through its subsidiaries, invests in, develops, licenses, and enforces patented technologies in the United States. The stock currently has a dividend yield of 13.59%. Currently, there is 1 analyst who rates Acacia Research a buy, 1 analyst rates it a sell, and 1 rates it a hold. Exclusive Offer: Get the latest Stock Analysis on ACTG - FREE TheStreet Quant Ratings rates Acacia Research as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself. Get the full Acacia Research Ratings Report from TheStreet Quant Ratings now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

RenaissanceRe Holdings (RNR) - FREE Research Report Todd Rider Fonner, who is Svp & Cio at RenaissanceRe Holdings, sold 1,500 shares at $111.01 on May 4, 2016. Following this transaction, the Svp & Cio owned 72,568 shares meaning that the stake was reduced by 2.03% with the 1,500-share transaction. The shares most recently traded at $111.96, up $0.95, or 0.85% since the insider transaction. Historical insider transactions for RenaissanceRe Holdings go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 1,500
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 7,000
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 53,366
The average volume for RenaissanceRe Holdings has been 311,200 shares per day over the past 30 days. RenaissanceRe Holdings has a market cap of $4.8 billion and is part of the financial sector and insurance industry. Shares are down 1.07% year-to-date as of the close of trading on Wednesday. RenaissanceRe Holdings Ltd. together with its subsidiaries, provides reinsurance and insurance coverages and related services in the United States and internationally. The company operates through Catastrophe Reinsurance, Specialty Reinsurance, and Lloyd's segments. The stock currently has a dividend yield of 1.11%. The company has a P/E ratio of 13.8. Currently, there are 3 analysts who rate RenaissanceRe Holdings a buy, 1 analyst rates it a sell, and 7 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on RNR - FREE TheStreet Quant Ratings rates RenaissanceRe Holdings as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full RenaissanceRe Holdings Ratings Report from TheStreet Quant Ratings now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Intercept Pharmaceuticals (ICPT) - FREE Research Report McMinn Rachel, who is Chief Strategy Officer at Intercept Pharmaceuticals, sold 130 shares at $147.49 on May 4, 2016. Following this transaction, the Chief Strategy Officer owned 14,087 shares meaning that the stake was reduced by 0.91% with the 130-share transaction. The shares most recently traded at $137.41, down $10.08, or 7.34% since the insider transaction. Historical insider transactions for Intercept Pharmaceuticals go as follows:

  • 4-Week # shares bought: 800
  • 4-Week # shares sold: 1,274
  • 12-Week # shares bought: 800
  • 12-Week # shares sold: 1,515
  • 24-Week # shares bought: 800
  • 24-Week # shares sold: 3,990
The average volume for Intercept Pharmaceuticals has been 754,000 shares per day over the past 30 days. Intercept Pharmaceuticals has a market cap of $3.6 billion and is part of the health care sector and drugs industry. Shares are down 6.84% year-to-date as of the close of trading on Wednesday. Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Currently, there are 7 analysts who rate Intercept Pharmaceuticals a buy, 2 analysts rate it a sell, and 2 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on ICPT - FREE TheStreet Quant Ratings rates Intercept Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Intercept Pharmaceuticals Ratings Report from TheStreet Quant Ratings now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Your Need to Know - Forward Look

Your Need to Know - Forward Look

3 Things Investors Can Do to Stay Strategic When the Market's Volatile

3 Things Investors Can Do to Stay Strategic When the Market's Volatile

How to Be a Tactical Investor in the Current Market

How to Be a Tactical Investor in the Current Market

How E-Mini S&P 500 Revolutionized Equity, Electronic Trading

How E-Mini S&P 500 Revolutionized Equity, Electronic Trading

Dow Gains, S&P 500 and Nasdaq Slip; Ford Hits 52-Week Low

Dow Gains, S&P 500 and Nasdaq Slip; Ford Hits 52-Week Low